NextCell Pharma publishes Interim Report 3 2021/2022

July 28, 2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report.NextCells share is traded on Nasdaq First North Growth Market under the ticker"NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Third quarter (2022-03-01 until 2022-05-31)

● Operating income amounted to 1 636 (906) TSEK.

● Operating result amounted to -9 307(-6 457)TSEK.

● Earnings per share* amounted to -0,27 (-0,19)SEK.

● Cash and bank amounted to 107 054 (150 754)TSEK.

● Solidity** amounted to 93,5 (96,9) %.

First nine months (2021-09-01 till 2022-05-31)

● Operating income amounted to 4 824 (3 074) TSEK.

● Operating result amounted to -25 991 (-20 079)TSEK.

● Earnings per share* amounted to -0,22 (-0,69)SEK.
‍

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523(34,056,943) shares. Average number of shares for the first nine months2021/2022: 34,379,523 (29,074,754) shares. Number of shares in NextCell as of May31, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the third quarter

● NextCell announced in early April that the stemcell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in Cellaviva's biobank, suffers from a serious blood disorder to be treated with stem cells at the Hematology Department at Rigshospitalet.

● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years
‍
● NextCell announced at the end of April that it is participating in a conference for world-leading cell therapies, the International Society for Cell and Gene Therapy 2022, in San Francisco and is represented by Mathias Svahn, CEO. Dr Svahn is a member of the Business Development and Finance Committee of ISCT.

● NextCell announced at the end of May that the company is presenting the ongoing clinical trial program with the drug candidate ProTrans lead cell therapy at the Advanced Therapies Congress in London on May 24-25.

● NextCell announced at the end of May that the European Patent Office(EPO) had issued an advance grant notice of the patent entitled "Allogeneic Composition" (publication numberEP3752598). The patent describes the method of manufacturing the drug candidate ProTrans and where the selection algorithm for selecting optimal cells and donors is the core. Patent protection is valid up to and i 2039.

Significant events after the reporting period

● NextCell announced in early June that all six children in the first part of the study with ProTrans. Patients will be monitored during the summer after which the safety of the treatment will be evaluated by an independent safety committee.

‍
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-07-2022 07:30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Instagram: https://www.instagram.com/cellaviva/

‍

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2020-06-24

NextCell Pharma AB’s rights issue heavily oversubscribed

The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees have been utilized. Through the Rights Issue, the Company receives approximately SEK 25.1 million before transaction costs. · 4,111,192 shares were subscribed using subscription rights · In addition, applications for subscription without using subscription rights corresponding to 11,750,102 shares

Read more Read more

2020-06-09

NextCell's phase II study is completed – a phase III is being prepared

NextCell Pharma AB ("NextCell") announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is completed according to plan. Data will be compiled and analyzed by independent statistician to be presented during the third quarter. “NextCell is now preparing a phase III trial in order to reach the market as soon as possible, in case of a positive result of the phase II study”, says Mathias Svahn, CEO. NextCell's drug candidate, ProTrans ™, developed for the treatment of type 1 diabetes, has, in

Read more Read more

2020-06-03

NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July

The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 25.1 million (the Rights Issue”), which was resolved by the Board of Directors on 15 May 2020 and approved by the extraordinary general meeting on 3 June 2020. The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority. Today, the Company also announces the intention of change of listing. The Company has obtained conditional

Read more Read more

2020-05-28

Invited to panel discussion; Post-Covid-19 world

NextCell Pharma AB ("NextCell") has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare - new challenges and main problems”. Doctor Lindsay Davies, Chief Scientific Officer at NextCell and researcher at Karolinska Institutet will join the panel. Today, 28[th] of May, international experts are having a one-day video conference. The conference is hosted by the Polish Medical Research Agency, Ministry of Health, Ministry of Development and is organized by the Kulski Foundation. The panel discussion is at 15:15 with opening speech

Read more Read more

2020-05-15

The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue

NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approval by an extraordinary general meeting in the Company. The Company’s largest shareholder Diamyd Medical AB and chairman of the Boad of Directors Anders Essen-Möller have undertaken to subscribe for their pro rata share in the Rights Issue. In total, the Rights Issue is covered by subscription

Read more Read more

2020-04-29

NextCell Pharma AB publishes its interim report for September 2019 - February 2020

NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income amounted to SEK 1 364 645 (435 051). · Operating result amounted to SEK -4 228 449 (-3 552 444). · Earnings per share* amounted to SEK -0,22 (-0,31). · Cash and bank amounted to SEK 10 700 725 (6 886 879). · Solidity** amounted to 80,2 (85,0) %. First six month (2019-09-01

Read more Read more

2020-03-20

NextCell in discussions about patients with covid-19

NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans. “We would like to emphasize that this information is preliminary. There are both administrative and regulatory challenges, but the intention from healthcare is to go forward with this. We will come back when and if further information is available, says Mathias Svahn, CEO of NextCell. "We advise against speculative share purchases in the

Read more Read more

2020-03-11

The stem cell company NextCell Pharma is preparing for a pivotal phase III trial

NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11. NextCell Pharma is currently running two parallel trials with ProTrans (Protrans-1 Phase I/II and ProTrans-Repeat) for the treatment of patients with type 1-diabetes. Ten out of a total of 15 patients in the phase II part of ProTrans-1 (ProTrans 2) have now left the trial and the last patient's last visit is scheduled for the end of June/July 2020. Thereafter, data will

Read more Read more